Literature DB >> 19408302

False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening.

Leo G M van Rossum1, Anne F van Rijn, Martijn G H van Oijen, Paul Fockens, Robert J F Laheij, Andre L M Verbeek, Jan B M J Jansen, Evelien Dekker.   

Abstract

Delayed return of immunochemical fecal occult blood test (iFOBT) samples to a laboratory might cause false negatives because of hemoglobin degradation. Quantitative iFOBT's became increasingly more accepted in colorectal cancer screening. Therefore, we studied the effects of delay between sampling and laboratory delivery on iFOBT performance. IFOBT positivity (>or=50 ng/ml hemoglobin) in colorectal cancer screening participants without delay between sampling and laboratory delivery (<5 days), was compared with positivity in participants with >or=5 and >or=7 days delay. Additionally, positive tests were stored at room temperature and retested 5 times within 10-14 days. The sampling date was reported by 61% (n = 3,767) of the participants: in 19% delay was >or=5 days and in 5% >or=7 days. Compared with no-delay, the adenoma detection rate was already significantly decreased after >or=5 days delay (OR 0.6; 95%CI 0.4-0.9). We retested iFOBT samples of 170 positives of which 139 (82%) had a colonoscopy: 45 (32%) had advanced adenomas (not colorectal cancer) and 8 (6%) had colorectal cancer. Mean daily fecal hemoglobin decrease was 29 ng/ml (S.D. 38 and median 11 ng/ml). In patients with advanced adenomas, hemoglobin in the sample was <50 ng/ml in 5 (11%) 2-3 days after the initial test and in 16 (36%) after 10-14 days. Seven days after the initial test, 2 (25%) colorectal cancer patients became false negative. Both had stage I colorectal cancer and initial values below 100 ng/ml, where the average for stage I is 532 ng/ml. Delay in sample return increased false negative immunochemical FOBT's. Mainly precursor lesions, but also colorectal cancer, will be missed due to delayed sample return.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408302     DOI: 10.1002/ijc.24458

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  Similar fecal immunochemical test results in screening and referral colorectal cancer.

Authors:  Sietze T van Turenhout; Leo G M van Rossum; Frank A Oort; Robert J F Laheij; Anne F van Rijn; Jochim S Terhaar sive Droste; Paul Fockens; René W M van der Hulst; Anneke A Bouman; Jan B M J Jansen; Gerrit A Meijer; Evelien Dekker; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

2.  Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy.

Authors:  Barcey T Levy; Camden Bay; Yinghui Xu; Jeanette M Daly; George Bergus; Jeffrey Dunkelberg; Carol Moss
Journal:  J Med Screen       Date:  2014-06-23       Impact factor: 2.136

3.  Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature.

Authors:  Chyke A Doubeni; Christopher D Jensen; Stacey A Fedewa; Virginia P Quinn; Ann G Zauber; Joanne E Schottinger; Douglas A Corley; Theodore R Levin
Journal:  J Am Board Fam Med       Date:  2016-11-12       Impact factor: 2.657

4.  Significant association of PRMT6 hypomethylation with colorectal cancer.

Authors:  Ranran Pan; Hang Yu; Jie Dai; Cong Zhou; Xiuru Ying; Jie Zhong; Jun Zhao; Yihan Zhang; Boyi Wu; Yiyi Mao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  J Clin Lab Anal       Date:  2018-06-21       Impact factor: 2.352

5.  Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results.

Authors:  Kunihiko Wakamura; Shin-Ei Kudo; Hideyuki Miyachi; Kenta Kodama; Seiko Hayashi; Yasuharu Maeda; Yushi Ogawa; Yuta Kouyama; Shin-Ichi Kataoka; Kazuki Kato; Katsuro Ichimasa; Masashi Misawa; Yuichi Mori; Toyoki Kudo; Takemasa Hayashi; Fumio Ishida; Shogo Ohkoshi
Journal:  Mol Clin Oncol       Date:  2015-07-01

6.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

7.  Evaluation of fecal immunochemical tests for colorectal cancer screening.

Authors:  Jeanette M Daly; Camden P Bay; Barcey T Levy
Journal:  J Prim Care Community Health       Date:  2013-05-12

Review 8.  Exosomal microRNA Biomarkers: Emerging Frontiers in Colorectal and Other Human Cancers.

Authors:  Oscar A Tovar-Camargo; Shusuke Toden; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2016-03-16       Impact factor: 5.225

Review 9.  Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.

Authors:  Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

Review 10.  Australia's national bowel cancer screening program: does it work for indigenous Australians?

Authors:  Aliki Christou; Judith M Katzenellenbogen; Sandra C Thompson
Journal:  BMC Public Health       Date:  2010-06-25       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.